Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G-R Burmester

Showing results (361-370 of 380) with videos related to

Pageof 38
Sort By:
Annals of the Rheumatic Diseases|June 30, 2000
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisJ S Smolen, F C Breedveld, G R Burmester, et al.
Annals of the Rheumatic Diseases|August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by BoersP Emery, C O Bingham, G R Burmester, et al.
Annals of the Rheumatic Diseases|May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III studyP Emery, C O Bingham, G R Burmester, et al.
Zeitschrift Fur Rheumatologie|May 2, 2012
[Biomarkers in rheumatology. Biomarkers and imaging for the diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the ArthroMark network funded by the Federal Ministry of Education and Research]T Häupl, H Appel, M Backhaus, et al.
Annals of the Rheumatic Diseases|December 3, 2003
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II studyL B A van de Putte, R Rau, F C Breedveld, et al.
Immunologic Research|July 2, 2011
Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomasPaula Hoff, T Gaber, K Schmidt-Bleek, et al.
Annals of the Rheumatic Diseases|November 21, 2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007D E Furst, F C Breedveld, J R Kalden, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 24, 2023
Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization testsE Habermann, L M Frommert, K Ghannam, et al.
Annals of the Rheumatic Diseases|December 1, 1999
Access to disease modifying treatments for rheumatoid arthritis patientsD E Furst, F C Breedveld, G R Burmester, et al.
Annals of the Rheumatic Diseases|October 9, 2003
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)D E Furst, F C Breedveld, J R Kalden, et al.
Pageof 38

Showing results (361-370 of 380) with videos related to

Sort By:
Pageof 38
Annals of the Rheumatic Diseases|June 30, 2000
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisJ S Smolen, F C Breedveld, G R Burmester, et al.
Annals of the Rheumatic Diseases|August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by BoersP Emery, C O Bingham, G R Burmester, et al.
Annals of the Rheumatic Diseases|May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III studyP Emery, C O Bingham, G R Burmester, et al.
Zeitschrift Fur Rheumatologie|May 2, 2012
[Biomarkers in rheumatology. Biomarkers and imaging for the diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the ArthroMark network funded by the Federal Ministry of Education and Research]T Häupl, H Appel, M Backhaus, et al.
Annals of the Rheumatic Diseases|December 3, 2003
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II studyL B A van de Putte, R Rau, F C Breedveld, et al.
Immunologic Research|July 2, 2011
Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomasPaula Hoff, T Gaber, K Schmidt-Bleek, et al.
Annals of the Rheumatic Diseases|November 21, 2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007D E Furst, F C Breedveld, J R Kalden, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 24, 2023
Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization testsE Habermann, L M Frommert, K Ghannam, et al.
Annals of the Rheumatic Diseases|December 1, 1999
Access to disease modifying treatments for rheumatoid arthritis patientsD E Furst, F C Breedveld, G R Burmester, et al.
Annals of the Rheumatic Diseases|October 9, 2003
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)D E Furst, F C Breedveld, J R Kalden, et al.
Pageof 38